share_log

关于自愿披露聚乙二醇伊立替康用于治疗伴脑转移的三阴性乳腺癌II期临床试验完成首例受试者入组的公告

Announcement on voluntary disclosure of polyethylene glycol irinotecan for the treatment of triple-negative breast cancer with brain metastasis completed the enrollment of the first patient

SZSI ·  Nov 13, 2024 00:00
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more